Drug Trial Radar · NCT02598661
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
289
Actual
Start
Jan 12, 2016
Primary completion
Oct 13, 2023
Study completion Oct 13, 2026
Sponsor
- Lead sponsor
- Geron CorporationIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment in Phase 2 study and to compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat sodium to placebo in transfusion-dependent participants with low or intermediate-1 risk MDS that is relapsed/refractory to ESA treatment in Phase 3 study. A separate Ventricular Repolarization Substudy (QTc Substudy) will evaluate the effect of imetelstat sodium on ventricular repolarization. An Extension Phase has been included to allow continued treatment for those participants who are benefitting from imetelstat sodium and to continue to evaluate the long-term safety, overall survival (OS), and disease progression, including progression to acute myeloid leukemia (AML) in transfusion-dependent participants with low or immediate-1 risk MDS that is relapsed/refractory to ESA treatment.
Conditions
- Myelodysplastic Syndromes
Interventions
Imetelstat SodiumDrug
Imetelstat sodium IV infusion.
PlaceboDrug
Imetelstat sodium-matching placebo IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Percentage of Participants Without Any Red Blood Cell (RBC) Transfusion During Any Consecutive 8-Weeks Period (All Participants)Time frame: Up to 5 years in Phase 2
- Phase 2: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks Period in Target PopulationTime frame: Up to 5 years in Phase 2
- Phase 3: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks PeriodTime frame: Up to 3.7 years in Phase 3
Locations
126 sites in 17 countries. Site status is shown where the registry gives one.
UAB Comprehensive Cancer Center
Birmingham, Alabama
Acrc/Arizona Clinical Research, Inc.
Tucson, Arizona
CBCC Global Research, Inc.
Bakersfield, California
UCLA Ronald Regan Medical Center
Los Angeles, California
Yale-New Haven Hospital (YNHH) - Smilow Cancer Hospital
New Haven, Connecticut
BRCR Medical Center
Plantation, Florida
University of South Florida (USF) - H. Lee Moffitt Cancer Center
Tampa, Florida
Franciscan Health
Indianapolis, Indiana
St. Agnes Healthcare, Inc
Baltimore, Maryland
Center for Cancer and Blood Disorders
Bethesda, Maryland
Washington University School of Medicine
St Louis, Missouri
University of New Mexico Cancer Center
Albuquerque, New Mexico
Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects
New York, New York
Columbia University Medical Center
New York, New York
Weill Cornell Medical College-New York Presbyterian Hospital
New York, New York
Cleveland Clinic Taussig Cancer
Cleveland, Ohio
The Ohio State Comprehensive Cancer Center
Columbus, Ohio
Prairie lakes Healthcare system, Inc
Watertown, South Dakota
Vanderbilt University Medical - Hematology-Oncology
Nashville, Tennessee
Texas Oncology/Methodist Charlton Cancer Center
Dallas, Texas
Simmons Comprehensive Cancer Center
Dallas, Texas
Fred Hutchinson Cancer Research Center (FHCRC)
Seattle, Washington
AZ Klina
Brasschaat, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven - Campus Gasthuisberg
Leuven, Belgium
ZAS Middelheim
Antwerp, Antwerpen, Belgium
ZAS Cadix
Antwerp, Antwerpen, Belgium
GZA Ziekenhuizen - Campus Sint
Wilrijk, Antwerpen, Belgium
AZ Sint-Jan Burgge-Oostende
Bruges, West-Vlaanderen, Belgium
Az Groeninge
Kortrijk, West-Vlaanderen, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
University of Alberta Hospital - Hematology Research
Edmonton, Alberta, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
FN Kralovske Vinohrady
Prague, Czechia
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Fakultni nemocnice Brno
Brno, Brno-město, Czechia
FN Hradec Kralove
Hradec Králové, Hradec Králové, Czechia
Showing 40 of 126 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.